2021 Year in Review - Gastrointestinal Cancer

RESOLVE: Significant Improvement in 3-Year Disease-Free Survival with Use of Perioperative SOX in Patients with Locally Advanced Gastric Cancer

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

Perioperative SOX treatment significantly improved 3-year disease-free survival in patients with locally advanced gastric cancer compared with adjuvant CapOx.

Zanidatamab plus Standard First-Line Chemotherapy Demonstrates Promising Antitumor Activity in Patients with HER2-Positive GEA

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

Results from a phase 2 clinical trial of the use of zanidatamab with standard first-line chemotherapy in patients with HER2-positive GEA show promising disease control rate and duration of response.

DESTINY-Gastric02: Clinical Efficacy Found with Use of Second-Line Trastuzumab Deruxtecan in Patients with Metastatic Gastric or Esophageal Junction Cancer

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

Results from a second-line trastuzumab deruxtecan phase 2 study in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer reveal promising response and safety.

Analysis of the Prognostic Value of Immune Checkpoints in Gastric Adenocarcinoma

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

Comprehensive analysis of immune checkpoints in gastric adenocarcinoma finds ICOSLG and CD70 may serve as prognostic biomarkers for gastric cancer.

PANTHERA: Triplet Pembrolizumab, Trastuzumab, and Chemotherapy First-Line Therapy Is Effective in HER2-Positive Advanced Gastric/GEJ Cancer Regardless of PD-L1 Status

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

Updated clinical data from the PANTHERA study shows promising efficacy for pembrolizumab triple therapy in HER2-positive advanced gastric and gastroesophageal junction (GEJ) cancer regardless of a patient’s PD-L1 status.

ATTRACTION-2: Nivolumab Conveys Survival Benefit for Patients with Advanced Gastric/GEJ Cancer When Used as Treatment Beyond Progression

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

Three-year ATTRACTION-2 follow-up results confirm the long-term efficacy of nivolumab in patients with previously treated advanced gastric/gastroesophageal junction (GEJ) cancer.

KEYNOTE-181: Improved OS in Patients with Advanced Esophageal Cancer Treated with Second-Line Pembrolizumab

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

KEYNOTE-181 results show improved overall survival in patients with advanced esophageal cancer treated with second-line pembrolizumab compared with chemotherapy.

ASCO Releases Clinical Guidelines for the Treatment of Patients with Advanced Esophageal Cancer

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

Recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma were released by an expert panel.

DELIVER: Real-World Data Analysis of Nivolumab Monotherapy in Advanced Gastric Cancer

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

Differences in survival time by tumor response were found during evaluation of nivolumab therapy in advanced gastric cancer.

CALGB 80803: PET-Directed Therapy After Induction Chemotherapy Yields Promising 5-Year Overall Survival in Patients with Esophageal Cancer

2021 Year in Review - Gastrointestinal Cancer | December 1, 2021

The use of PET to direct therapy after nonresponse to induction chemotherapy improved overall survival in patients with resectable esophageal cancer.

Loading More Articles